Residency · Residency · Preventive Medicine

Cardiovascular Disease Risk Assessment and Prevention

Overview

CVD is the leading cause of death in the U.S. (~700,000 deaths/year) and globally (~17.9 million deaths/year) Major components: coronary heart disease (CHD), stroke, heart failure, peripheral artery disease. Primary prevention focuses on risk factor modification before a first cardiovascular event. The Pooled Cohort Equations (PCE) estimate 10-year atherosclerotic CVD (ASCVD) risk and guide clinical decision-making. Population-level strategies (trans fat bans, sodium reduction, tobacco control) complement individual risk management. Declining CVD mortality since the 1960s is attributed roughly equally to risk factor reduction and improved treatment.

Risk Assessment

Pooled Cohort Equations (PCE)

Estimate 10-year risk of first ASCVD event (MI, stroke) in adults 40-79. Variables: age, sex, race (White/Black), total cholesterol, HDL cholesterol, systolic BP, BP treatment status, diabetes, smoking status. Risk categories: low (<5%), borderline (5-7.4%), intermediate (7.5-19.9%), high (>=20%) Limitations: overestimates risk in some populations (higher SES, non-Black minorities); developed from older cohorts; limited racial/ethnic representation. Validated primarily in non-Hispanic White and Black adults; less accurate for Hispanic, Asian, South Asian populations.

Risk-Enhancing Factors

Family history of premature ASCVD (male <55, female <65) Chronic kidney disease. Metabolic syndrome. Chronic inflammatory conditions (RA, psoriasis, lupus, HIV) South Asian ancestry. Preeclampsia or premature menopause. Elevated Lp(a), apoB, hsCRP, ABI <=0.9. These factors help reclassify borderline/intermediate-risk patients.

Coronary Artery Calcium (CAC) Scoring

CT-based quantification of coronary artery calcification. CAC = 0: very low 10-year ASCVD risk (<5%) regardless of PCE estimate; may defer statin. CAC >=100 or >=75th percentile for age/sex: favors statin initiation. Most useful for patients in the intermediate-risk range where treatment decision is uncertain. Not recommended if the decision to treat is already clear (very low or very high risk) Radiation exposure: ~1 mSv (equivalent to mammogram)

Lifetime Risk

10-year risk may be low in younger adults despite high lifetime risk. Lifetime risk of ASCVD at age 45: ~60% for men, ~55% for women with >=2 risk factors vs. ~5% with optimal risk factors. Useful for motivating lifestyle modification in young adults with low short-term but high lifetime risk.

Primary Prevention Strategies

Statin Therapy

ACC/AHA 2018 guidelines define four statin benefit groups: Clinical ASCVD (secondary prevention) LDL-C >=190 mg/dL (no risk calculation needed) Diabetes, age 40-75, LDL-C 70-189. Age 40-75, LDL-C 70-189, 10-year ASCVD risk >=7.5%. Shared decision-making recommended, especially for borderline/intermediate risk. High-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg): reduce LDL by >=50%. Moderate-intensity statins: reduce LDL by 30-49%. NNT for primary prevention with statins over 5 years: ~50-100 (varies by baseline risk) Side effects: myalgias (~5-10%, mostly nocebo effect), new-onset diabetes (~0.1%/year), rarely rhabdomyolysis. Statin intolerance: true in ~2-3% of patients; try alternate statin, lower dose, alternate-day dosing.

Aspirin for Primary Prevention

Previous recommendation: low-dose aspirin for high CVD risk adults. Current evidence (ARRIVE, ASPREE, ASCEND): bleeding risk offsets cardiovascular benefit in most primary prevention patients. USPSTF (2022): recommends against initiating aspirin for primary CVD prevention in adults >=60; individual decision for ages 40-59 with >=10% 10-year risk (C recommendation) ACC/AHA: aspirin should rarely be used in primary prevention; avoid if increased bleeding risk.

Blood Pressure Management

Target <130/80 mmHg per ACC/AHA 2017 (based on SPRINT) Lifestyle modifications: DASH diet, sodium reduction, physical activity, weight loss, alcohol moderation. Pharmacotherapy: ACEi/ARB, calcium channel blocker, thiazide diuretic as first-line. See Topic 29 for detailed sodium reduction strategies.

Lipid Management Beyond Statins

Ezetimibe: add-on to statin if LDL goal not met; 15-20% further LDL reduction. PCSK9 inhibitors (evolocumab, alirocumab): powerful LDL reduction (~60%); primarily for high-risk secondary prevention or familial hypercholesterolemia. Bempedoic acid: for statin-intolerant patients; reduces LDL by ~18%; CLEAR Outcomes trial showed CVD benefit. Icosapent ethyl (Vascepa): reduces CV events in statin-treated patients with elevated triglycerides (REDUCE-IT trial); EPA-only formulation. Inclisiran: siRNA targeting PCSK9; twice-yearly injection; reduces LDL by ~50%.

Diabetes Management for CVD Prevention

GLP-1 receptor agonists and SGLT2 inhibitors: reduce major adverse cardiovascular events independent of glucose lowering. SGLT2 inhibitors: heart failure and renal protection. Comprehensive diabetes management reduces microvascular complications; CVD risk reduction requires aggressive BP and lipid management.

Population-Level Interventions

Trans Fat Elimination

Artificial trans fats (partially hydrogenated oils) increase LDL, decrease HDL, promote inflammation. FDA ban on partially hydrogenated oils in food supply (2018, enforced 2020) New York City trans fat ban (2006): associated with 6.2% decline in MI and stroke hospitalizations. WHO REPLACE framework: global effort to eliminate industrial trans fats by 2023.

Sodium Reduction

Population sodium reduction strategies (see Topic 29) Estimated 280,000-500,000 deaths preventable over 10 years with FDA voluntary targets.

Tobacco Control

See Topic 28; smoking cessation is the single most impactful individual CVD risk reduction intervention. CVD risk drops ~50% within 1 year of cessation.

Physical Activity Promotion

150 min/week moderate or 75 min/week vigorous activity reduces CVD risk by 20-30%. Even modest increases in physical activity from sedentary baseline produce significant benefit. Community-level interventions: built environment, workplace programs, school-based programs.

<image>A flowchart showing the ACC/AHA primary prevention statin decision algorithm: starting with age 40-75 and LDL 70-189 mg/dL, then 10-year ASCVD risk calculation using the Pooled Cohort Equations. Branches show: low risk (<5%) -- lifestyle emphasis; borderline (5-7.4%) -- consider if risk enhancers present; intermediate (7.5-19.9%) -- shared decision-making, consider CAC if uncertain; high (>=20%) -- high-intensity statin recommended. Risk-enhancing factors and CAC score thresholds are annotated at decision nodes. CVD prevention education illustration.</image>

<image>A comparative bar chart showing the relative CVD risk reduction from major primary prevention interventions: smoking cessation (~50% within 1 year), statin therapy (~25-30% relative risk reduction), blood pressure control to <130/80 (~20-25%), regular physical activity (~20-30%), DASH diet (~15-20%), and weight loss of 5-10% (~10-15%). The chart emphasizes that combined lifestyle modification produces cumulative risk reduction greater than any single intervention. CVD prevention education illustration.</image>

<image>An infographic explaining the coronary artery calcium (CAC) score and its role in clinical decision-making. A CT scan image of coronary calcification is shown alongside a scoring scale: CAC=0 (very low risk, may defer statin), CAC 1-99 (mild calcification, individualize), CAC 100-299 (moderate, favors statin), CAC >=300 (extensive, strong indication for statin). Clinical scenarios illustrate when CAC is most useful (intermediate 10-year risk, uncertain treatment decision). CAC scoring education illustration.</image>

Clinical Pearls

A CAC score of 0 in an intermediate-risk patient provides strong reassurance -- 10-year event rate is <5%, and statin therapy can reasonably be deferred with repeat assessment in 5-10 years. Aspirin for primary CVD prevention has been dramatically de-emphasized -- the ASPREE trial showed increased bleeding with no mortality benefit in healthy older adults. Statin myalgia is largely a nocebo effect -- the SAMSON trial showed similar symptom rates on statin, placebo, and no-tablet phases; true intolerance is rare. Trans fat elimination from the food supply is one of the most successful population-level CVD interventions -- measurably reduced MI hospitalizations in early-adopter jurisdictions. For boards: know the four statin benefit groups, PCE risk thresholds, CAC score interpretation, current aspirin primary prevention recommendations, and population-level interventions (trans fat ban, sodium reduction)

References

• Arnett DK, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596-e646.
• Grundy SM, et al. 2018 AHA/ACC cholesterol clinical practice guideline. Circulation. 2019;139(25):e1082-e1143.
• Gaziano JM, et al. Use of aspirin to reduce risk of initial vascular events (ARRIVE). Lancet. 2018;392(10152):1036-1046.
• McNeil JJ, et al. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly (ASPREE). N Engl J Med. 2018;379(16):1509-1518.
• Blaha MJ, et al. Role of coronary artery calcium score of zero and other negative risk markers. Circulation. 2019;140(11):e569-e595.

Read this lecture as Markdown